TapImmune Inc. (OTCMKTS:TPIV) Surges On Financing News

[[tagnumber 0]][[tagnumber 1]]TapImmune Inc. (OTCMKTS:TPIV) had an impressive performance throughout most of May, gaining more than 100% in value. The final days of the month weren’t that favorable for the company stock, but [[tagnumber 2]]TPIV[[tagnumber 3]] didn’t lose a lot of altitude.[[tagnumber 4]] [[tagnumber 0]] [[tagnumber 4]] [[tagnumber 0]]Of course, one thing that is keeping investor confidence in [[tagnumber 2]]TPIV[[tagnumber 3]] strong are the numbers that the company recorded in the first quarter of this year. Here are just some of those of prime interest that were contained in the balance sheet for the period ended March 31, 2015.[[tagnumber 4]] [[tagnumber 0]] [[tagnumber 4]] [[tagnumber 13]] [[tagnumber 14]]cash: $1.45 million[[tagnumber 15]] [[tagnumber 14]]current assets: $1.53 million[[tagnumber 15]] [[tagnumber 14]]current liabilities: $3.3 million[[tagnumber 15]] [[tagnumber 14]]quarterly revenues: $0[[tagnumber 15]] [[tagnumber 14]]quarterly net loss: $981 thousand[[tagnumber 15]] [[tagnumber 24]] [[tagnumber 0]] [[tagnumber 4]] [[tagnumber 0]]We see that the company has a decent amount of cash on hand, but still hasn’t managed to generate revenues. This is due to the fact that [[tagnumber 2]]TPIV[[tagnumber 3]] is still a development stage company with ongoing trials for the treatment of cancer.[[tagnumber 4]] [[tagnumber 0]] [[tagnumber 4]] [[tagnumber 0]]After the depressing performance from the end of May we saw [[tagnumber 2]]TPIV[[tagnumber 3]] gain 13.04% in yesterday’s session and close at $0.39 per share. Furthermore, the company announced an agreement for a near–term capital infusion that will provide the company with up to $4.93 million in order to carry on with its operations.[[tagnumber 4]] [[tagnumber 0]] [[tagnumber 4]] [[tagnumber 0]]With such news it’s no wonder that [[tagnumber 2]]TPIV[[tagnumber 3]] has started today’s session positively as well. So far the ticker is 10.64% higher from yesterday’s close. This, however, doesn’t mean that you should skip doing your due diligence and weighing out the risks before putting any money on the line.[[tagnumber 4]]